- Home
- NMAI vs ALT Comparison
NMAI vs ALT Comparison
Compare NMAI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMAI | ALT |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.6M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NMAI | ALT |
|---|---|---|
| Price | $13.85 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 106.3K | ★ 4.4M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $11.99 | $2.56 |
| 52 Week High | $14.38 | $6.44 |
Technical Indicators
Market Signals| Indicator | NMAI | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 60.46 |
| Support Level | $13.59 | $2.62 |
| Resistance Level | $13.90 | $3.26 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 45.71 | 64.02 |
Price Performance
Historical ComparisonAbout NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.